Does Oxygen Cause Cancer to Spread?

Oxygen does not cause cancer to spread. The relationship runs in the opposite direction: tumors that outgrow their blood supply become starved of oxygen, and that oxygen-deprived state activates a cascade of molecular changes that make cancer cells more mobile, more invasive, and better at seeding new tumors in distant organs. The misconception persists partly because oxygen is chemically reactive and partly because the biology is genuinely counterintuitive. But the evidence, from cell studies to animal models to population-level data, consistently points to low oxygen inside tumors as one of the strongest promoters of metastasis.

How Low Oxygen Inside Tumors Drives Spread

Solid tumors grow fast, often faster than the blood vessels feeding them can keep up. The interior of a tumor frequently becomes hypoxic, meaning it has far less oxygen than healthy tissue. When cells sense this oxygen shortage, they activate a protein called HIF-1α, which flips on a suite of genes designed to help cells survive harsh conditions. In normal tissue, that response is useful. In a tumor, it becomes dangerous. HIF-1α triggers programs that promote invasion into surrounding tissue, stimulate the growth of new blood vessels, reprogram how cells generate energy, and help cancer cells resist death signals.¹

One of the most consequential things HIF-1α does is drive the production of a growth signal called VEGF, which tells nearby blood vessels to sprout new branches toward the tumor. This sounds like it would help the tumor get the oxygen it needs, and it does, but poorly. The new vessels that form under hypoxic pressure are structurally abnormal, with irregular branching and leaky walls.² Leaky vessels create pockets of inconsistent blood flow, which means parts of the tumor remain hypoxic even as new vessels form. Worse, those leaky junctions give cancer cells an easier route into the bloodstream.

Hypoxia also pushes cancer cells through a transformation known as epithelial-mesenchymal transition, or EMT, where cells that were once stuck in place acquire the ability to crawl and migrate. Pancreatic cancer cells exposed to intermittent cycles of low oxygen showed enhanced invasive ability and characteristics of stem-like cells, a particularly therapy-resistant population.³ Separate experiments confirmed that cells selected by intermittent hypoxia displayed molecular markers of EMT and increased survival, invasion, and therapy resistance.⁴

Beyond the tumor itself, hypoxia helps cancer prepare distant organs for colonization. Prostate cancer cells grown under low oxygen released tiny vesicles called exosomes that traveled to potential metastatic sites and remodeled the tissue there, increasing the activity of enzymes that break down the structural scaffold between cells and recruiting immune cells that further reshape the environment.⁵ An enzyme called lysyl oxidase, secreted by hypoxic tumors, has been shown to be essential for creating a hospitable niche at distant sites, and blocking it reduced metastasis.⁶ In other words, a low-oxygen primary tumor can reach out and remodel organs it has never touched, preparing the soil before a single cancer cell arrives.

Hypoxia as an Immune Shield

Your immune system, particularly killer T cells and natural killer cells, is one of the strongest defenses against cancer spreading. But those immune cells need oxygen too. In prostate tumors, researchers found that T cells congregated in well-oxygenated regions of the tumor while the hypoxic zones were largely devoid of any T cell infiltration. The researchers described these low-oxygen pockets as potential “islands of immune privilege” where cancer cells could hide from immune attack and resist immunotherapy.⁷

Similar findings appeared in glioblastoma, an aggressive brain cancer. In normal host animals, killer T cells tended to be drawn into hypoxic areas but were rendered ineffective there, contributing to immune tolerance rather than immune attack.⁸ The pattern across different tumor types is consistent: low oxygen suppresses the immune cells that would otherwise keep cancer in check, and that suppression is mediated through the same HIF-1α pathway that drives invasion and blood vessel growth.

What Happens When You Add More Oxygen

If low oxygen promotes spread, a natural question is whether raising oxygen levels could slow it. The animal research on this is surprisingly encouraging. Mice breathing supplemental oxygen (hyperoxia) showed improved immune responses inside their tumors: more T cell infiltration, stronger inflammatory signaling, weaker suppression by regulatory T cells, and better tumor regression. Breathing extra oxygen even promoted regression of spontaneous metastases from breast tumors that had already spread to the lungs.⁹ The same research group found that these immune-boosting effects of supplemental oxygen improved the effectiveness of both adoptive cell transfer (giving patients lab-grown immune cells) and checkpoint immunotherapy drugs.¹⁰

In a lung cancer model, mice treated with daily sessions of breathing higher-than-normal oxygen concentrations showed no increase in tumor progression. Instead, the treatment suppressed metastasis and improved long-term survival, working through a metabolic pathway that disrupted the cancer cells’ ability to use certain amino acids during spread.¹¹

Hyperbaric oxygen therapy, which delivers pure oxygen at pressures above normal atmospheric levels, has been studied more directly in clinical settings. A review of the available evidence found no indication that hyperbaric oxygen stimulates tumor growth or enhances cancer recurrence, and noted hints that it might inhibit certain cancer subtypes.¹² In a mouse model of lung cancer, hyperbaric oxygen significantly suppressed tumor growth and reduced tumor hypoxia.¹³ And a safety evaluation in cancer patients with solid tumors found no significant link between the number of hyperbaric oxygen sessions and either metastasis or mortality.¹⁴

Fixing the Blood Vessels Instead of Just Flooding the Tumor

An alternative strategy to simply increasing oxygen supply is to fix the chaotic blood vessels within tumors so they deliver oxygen more evenly. This approach, called vascular normalization, has been shown to reduce tumor invasion and metastasis while also making chemotherapy, radiation, and immunotherapy work better.¹⁵ In one set of experiments, reducing the activity of a single oxygen-sensing enzyme in blood vessel cells didn’t change how many vessels a tumor had, but it normalized their structure, improved blood flow and oxygenation, and inhibited invasion and metastasis.¹⁶

This matters for radiation therapy as well. Radiation kills cancer cells partly by generating chemical damage that gets “fixed” in place by oxygen molecules. The more oxygen present when radiation hits DNA, the harder it is for the cell to repair the damage.¹⁷ Hypoxic tumors resist radiation precisely because they lack the oxygen needed to make radiation damage permanent. This is why oncologists have long recognized tumor hypoxia as a problem, not a solution. Exercise, for instance, has been explored as a way to boost tumor blood flow before radiation sessions. Preclinical research in prostate cancer models showed that exercise reduced hypoxia inside tumors and improved natural killer cell infiltration.¹⁸

The Reactive Oxygen Species Complication

Here is where the picture gets genuinely complicated, and where some of the confusion about “oxygen causing cancer spread” likely originates. Oxygen metabolism generates byproducts called reactive oxygen species, or ROS. These are unstable, highly reactive molecules, and at low to moderate levels, they act as signaling molecules that can activate cell proliferation, migration, invasion, and blood vessel growth.¹⁹ That sounds alarming, and it is a real biological effect. In breast cancer cells with mitochondrial dysfunction, increased ROS production promoted cell movement and invasion partly by stabilizing HIF-1α, the same protein activated by low oxygen.²⁰ In liver cancer, a specific genetic element promoted cancer cell migration by boosting intracellular ROS levels.²¹

But ROS are a double-edged sword, and at high levels they damage and kill cancer cells. This is actually one of the mechanisms behind both radiation and certain chemotherapy drugs. The key distinction is that ROS are not the same as breathing oxygen. ROS are produced inside cells as a consequence of metabolism, and their levels depend on mitochondrial function, antioxidant defenses, and dozens of other intracellular factors, not simply on how much oxygen you inhale. Conflating “oxygen in the air” with “reactive oxygen species inside a cell” is like conflating “water in a lake” with “a flood in your basement.” They are related, but one does not automatically produce the other.

The Antioxidant Paradox

If ROS can promote cancer cell migration, you might assume that antioxidants, which neutralize ROS, would prevent spread. The evidence suggests the opposite. When cancer cells break free from a primary tumor and enter the bloodstream, they face intense oxidative stress. That stress actually serves as a barrier, killing most circulating cancer cells before they can reach a new organ. Antioxidants, whether taken as supplements or produced naturally by the body, can reduce that oxidative barrier and allow more cancer cells to survive the journey and colonize distant sites.²²

In mouse melanoma models, circulating cancer cells showed higher levels of oxidative stress than cells sitting in the primary tumor, and that stress interfered with metastasis formation. When mice were given antioxidants, the circulating cells survived better and metastatic disease increased.²³ This is a striking finding because it means that the body’s own oxidative defenses, powered in part by oxygen-derived chemistry, are one of the natural checkpoints against metastasis. Removing that checkpoint with antioxidant supplements can backfire.

How Cancer Cells Manage Their Own Energy During Spread

Cancer cells are metabolically flexible in ways that make them hard to pin down. A longstanding observation is that many tumors rely heavily on a form of sugar metabolism that does not require oxygen, even when oxygen is available. But the story during metastasis is more complex. When cancer cells are traveling through the bloodstream as circulating tumor cells, they rely on oxygen-dependent energy production to power their journey. This shift is facilitated by increased levels of a metabolic regulator called PGC-1α.²⁴ When those cells cluster together after arriving at a new organ, they shift back toward oxygen-independent metabolism to reduce ROS production and maintain fitness, while still keeping the capacity for oxygen-dependent metabolism in reserve.²⁴

Each metastatic destination presents its own metabolic challenges, including differences in fuel availability, oxygen levels, and oxidative stress.²⁵ Cancer cells that successfully colonize the liver face a different metabolic landscape than those that settle in bone or lung. This adaptability, the ability to switch between oxygen-using and oxygen-independent energy production depending on the moment, is itself increasingly recognized as a driver of treatment resistance and tumor diversity.²⁶

Why Perioperative Oxygen Remains Contested

If the animal research on supplemental oxygen is so encouraging, you might wonder why oncologists are not already prescribing it broadly. One practical area where the question has been tested in humans is perioperative care: how much supplemental oxygen to give patients during and after cancer surgery. Here, the clinical picture is less clear-cut. Some trials have suggested that high-concentration oxygen during surgery increases postoperative complications, which can delay the start of follow-up chemotherapy or radiation. The effects on long-term cancer survival remain conflicting across studies. And in laboratory conditions, high oxygen concentrations increased ROS production and oxidative stress in cancer cells, which in some contexts promoted certain features associated with spread, including early signs of EMT and molecular signals tied to blood vessel growth.²⁷

The perioperative context is unique because surgery creates inflammation, tissue damage, and immune suppression simultaneously. Oxygen’s effects during that narrow window may differ from its effects on an established tumor or during long-term treatment. Researchers have not yet sorted out whether perioperative hyperoxia’s complications stem from the oxygen itself or from its interactions with surgery-related inflammation. This is the one area where a blanket “more oxygen is better” claim does not hold up well, and it is worth watching for future trial results.

People Living at High Altitude Get Less Cancer

One of the most intriguing pieces of the puzzle comes from population studies of people living at high elevation, where every breath delivers less oxygen than at sea level. You might expect chronic mild hypoxia to mimic what happens inside tumors and drive more cancer. It does not. Multiple studies have found that populations living at high altitude have reduced cancer mortality across a broad spectrum of cancer types.²⁸ The physiological adaptations to high altitude, including changes in blood sugar regulation, lipid metabolism, iron handling, and increased physical activity, appear to create a metabolic environment that is generally unfavorable for cancer.²⁹

This seems to contradict the idea that tumor hypoxia promotes cancer, but the contradiction dissolves on closer inspection. The hypoxia inside a tumor is extreme, chaotic, and localized, with some regions getting almost no oxygen at all. The mild, whole-body hypoxia experienced at altitude is steady and triggers orderly systemic adaptations including lower blood sugar, reduced obesity rates, and less inflammation. These are very different physiological situations, even though both involve reduced oxygen. It is a useful reminder that the dose, distribution, and context of oxygen deprivation matter enormously, and that simple narratives about oxygen being “good” or “bad” for cancer miss the point.